

EMEA Point-Of-Care Diagnostics Market Size, Share & Trends Analysis Report By Product (Glucose Testing, Cancer Marker, Coagulation Testing, Infectious Disease), By End-use (Clinics, Home), By Region (Europe, MEA), And Segment Forecasts, 2025 - 2033

<https://marketpublishers.com/r/E41936188EEEEEN.html>

Date: August 2025

Pages: 136

Price: US\$ 5,950.00 (Single User License)

ID: E41936188EEEEEN

Abstracts

EMEA point-of-care diagnostics Market Trends

The EMEA point-of-care (POC) diagnostics market size was estimated at USD 14.08 billion in 2024 and is projected to reach USD 23.13 billion by 2033, growing at a CAGR of 6.2% from 2025 to 2033. This market emphasizes rapid diagnostic solutions designed for near-patient testing, enabling timely clinical decisions and improved healthcare outcomes. POC diagnostics in Europe, Middle East, and Africa (EMEA) region span a range of applications, including infectious disease detection, cardiovascular monitoring, blood glucose testing, pregnancy screening, and other critical areas that require swift and reliable results. These solutions are increasingly utilized across hospitals, clinics, and home care settings, reducing the need for centralized laboratory testing.

The market is supported by advancements in portable devices, user-friendly testing kits, and digital connectivity that allow seamless data sharing and integration with healthcare systems. Growing demand for decentralized healthcare, along with efforts to improve diagnostic access in remote areas across Europe, the Middle East, and Africa, is encouraging adoption. Technological innovations, such as microfluidics, lateral flow assays, and molecular diagnostics at the point of care, are reshaping the landscape by enabling faster turnaround times and expanding the range of testable conditions. For instance, in June 2023, Sysmex introduced the first point-of-care antimicrobial susceptibility testing system in Europe. Using proprietary microfluidic technology, this

system delivers results in as little as 30 minutes, supporting rapid identification of resistant pathogens and optimizing treatment decisions in clinical settings.

Furthermore, favorable healthcare initiatives and increased awareness of early disease detection are driving investments in POC technologies across the Europe, Middle East, and Africa (EMEA) region. Public and private sector collaborations are strengthening diagnostic networks and accelerating the adoption of cost-effective, rapid testing solutions. The growing focus on digital health integration, supported with telemedicine and connected diagnostic platforms, is expected to further improve patient management and expand the reach of POC diagnostics in both developed and emerging markets within the region.

These innovations are transforming the global high throughput screening landscape by enabling faster, more precise, and cost-effective drug discovery solutions. The integration of AI-driven analytics, microfluidics, and advanced 3D cell models is improving the reliability of screening outcomes and streamlining decision-making. With pharmaceutical and biotechnology companies focusing on efficient lead identification and early-stage validation, these advancements are expected to strengthen drug development pipelines and accelerate time-to-market for novel therapeutics in the coming years.

EMEA Point-of-Care Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the EMEA point-of-care diagnostics market based on product, end-use, and region:

Product Outlook (Revenue, USD Million, 2021 - 2033)

Glucose Testing

Hb1Ac Testing

Coagulation Testing

Fertility/ Pregnancy

Infectious Disease

HIV POC

Clostridium Difficile POC

HBV POC

Pneumonia or Streptococcus Associated Infections

Respiratory Syncytial Virus (RSV) POC

HPV POC

Influenza/ Flu POC

HCV POC

MRSA POC

TB and Drug-resistant TB POC

HSV POC

COVID-19

Other Infectious Diseases

Cardiac Markers

Thyroid Stimulating Hormone

Hematology

Primary Care Systems

Decentralized Clinical Chemistry

Feces

Lipid Testing

Cancer Marker

Blood Gas/ Electrolytes

Ambulatory Chemistry

Drug of Abuse (DOA) Testing

Autoimmune Diseases

Urinalysis/ Nephrology

End-use Outlook (Revenue, USD Million, 2021 - 2033)

Clinics

Pharmacy & Retail Clinics

Physician Office

Urgent Care Clinics

Hospitals

Home

Assisted Living Healthcare Facilities

Laboratory

Regional Outlook (Revenue, USD Million, 2021 - 2033)

Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

This report can be delivered to the clients within 3 Business Days

Contents

CHAPTER 1. EMEA POINT-OF-CARE DIAGNOSTICS MARKET: METHODOLOGY AND SCOPE

- 1.1. Market Segmentation and Scope
 - 1.1.1. Segment Definitions
 - 1.1.1.1. Product Segment
 - 1.1.1.2. End Use Segment
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Objectives
 - 1.4.1. Objective - 1
 - 1.4.2. Objective - 2
 - 1.4.3. Objective - 3
- 1.5. Research Methodology
- 1.6. Information Procurement
 - 1.6.1. Purchased Database
 - 1.6.2. GVR's Internal Database
 - 1.6.3. Secondary Sources
 - 1.6.4. Primary Research
- 1.7. Information or Data Analysis
 - 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
 - 1.9.1. Commodity Flow Analysis
- 1.10. List of Secondary Sources
- 1.11. List of Abbreviations

CHAPTER 2. EMEA POINT-OF-CARE DIAGNOSTICS MARKET: EXECUTIVE SUMMARY

- 2.1. Market Snapshot
- 2.2. Product Snapshot
- 2.3. End Use Snapshot
- 2.4. Competitive Landscape Snapshot

CHAPTER 3. EMEA POINT-OF-CARE DIAGNOSTICS MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
 - 3.2.1. Parent Market Outlook
 - 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.4. Market Drivers Analysis
 - 3.4.1. Rising Burden of Chronic and Infectious Diseases
 - 3.4.2. Shift Toward Decentralized Healthcare
 - 3.4.3. Technological Advancements in POC Devices
- 3.5. Market Restraint Analysis
 - 3.5.1. Regulatory and Quality Compliance Challenges
 - 3.5.2. Limited Access in Low-Income Regions
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
- 3.8. Pipeline Analysis

CHAPTER 4. EMEA POINT-OF-CARE DIAGNOSTICS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS

- 4.1. EMEA Point-Of-Care Diagnostics Market: Product Movement Analysis
- 4.2. Glucose Testing
 - 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3. Hb1Ac Testing
 - 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4. Coagulation Testing
 - 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Fertility/Pregnancy
 - 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Infectious Disease
 - 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 4.6.2. HIV POC
 - 4.6.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 4.6.3. Clostridium Difficile POC
 - 4.6.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 4.6.4. HBV POC
 - 4.6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 4.6.5. Pneumonia or Streptococcus Associated Infections
 - 4.6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

- 4.6.6. Respiratory Syncytial Virus (RSV) POC
 - 4.6.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.7. HPV POC
 - 4.6.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.8. Influenza/Flu POC
 - 4.6.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.9. HCV POC
 - 4.6.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.10. MRSA POC
 - 4.6.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.11. TB and Drug-resistant TB POC
 - 4.6.11.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.12. HSV POC
 - 4.6.12.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.13. COVID-19
 - 4.6.13.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.14. Urinalysis/Nephrology
 - 4.6.14.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.7. Cardiac Markers
 - 4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.8. Thyroid Stimulating Hormone
 - 4.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.9. Hematology
 - 4.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.10. Primary Care Systems
 - 4.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.11. Decentralized Clinical Chemistry
 - 4.11.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.12. Feces
 - 4.12.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.13. Lipid Testing
 - 4.13.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.14. Cancer Marker
 - 4.14.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.15. Blood Gas/Electrolytes
 - 4.15.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.16. Ambulatory Chemistry
 - 4.16.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.17. Drug of Abuse (DOA) Testing

- 4.17.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.18. Autoimmune Diseases
 - 4.18.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.19. Urinalysis/Nephrology
 - 4.19.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

CHAPTER 5. EMEA POINT-OF-CARE DIAGNOSTICS MARKET: END USE ESTIMATES & TREND ANALYSIS

- 5.1. EMEA Point-Of-Care Diagnostics Market: End Use Movement Analysis
- 5.2. Clinics
 - 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 5.2.2. Pharmacy & Retail Clinics
 - 5.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 5.2.3. Physician Office
 - 5.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 5.2.4. Urgent Care Clinics
 - 5.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.3. Hospitals
 - 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. Home
 - 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Assisted Living Healthcare Facilities
 - 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Laboratory
 - 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

CHAPTER 6. EMEA POINT-OF-CARE DIAGNOSTICS MARKET: REGIONAL BUSINESS ANALYSIS

- 6.1. Regional Market Snapshot
- 6.2. Europe
 - 6.2.1. Europe EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
 - 6.2.2. UK
 - 6.2.2.1. UK EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
 - 6.2.2.2. Key Country Dynamics
 - 6.2.2.3. Regulatory Framework
 - 6.2.2.4. Reimbursement Scenario
 - 6.2.2.5. Competitive Scenario

6.2.3. Germany

6.2.3.1. Germany EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)

6.2.3.2. Key Country Dynamics

6.2.3.3. Regulatory Framework

6.2.3.4. Reimbursement Scenario

6.2.3.5. Competitive Scenario

6.2.4. Spain

6.2.4.1. Spain EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)

6.2.4.2. Key Country Dynamics

6.2.4.3. Regulatory Framework

6.2.4.4. Reimbursement Scenario

6.2.4.5. Competitive Scenario

6.2.5. France

6.2.5.1. France EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)

6.2.5.2. Key Country Dynamics

6.2.5.3. Regulatory Framework

6.2.5.4. Reimbursement Scenario

6.2.5.5. Competitive Scenario

6.2.6. Italy

6.2.6.1. Italy EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)

6.2.6.2. Key Country Dynamics

6.2.6.3. Regulatory Framework

6.2.6.4. Reimbursement Scenario

6.2.6.5. Competitive Scenario

6.2.7. Denmark

6.2.7.1. Denmark EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)

6.2.7.2. Key Country Dynamics

6.2.7.3. Regulatory Framework

6.2.7.4. Reimbursement Scenario

6.2.7.5. Competitive Scenario

6.2.8. Sweden

6.2.8.1. Sweden EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)

6.2.8.2. Key Country Dynamics

6.2.8.3. Regulatory Framework

6.2.8.4. Reimbursement Scenario

6.2.8.5. Competitive Scenario

6.2.9. Norway

6.2.9.1. Norway EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)

6.2.9.2. Key Country Dynamics

6.2.9.3. Regulatory Framework

6.2.9.4. Reimbursement Scenario

6.2.9.5. Competitive Scenario

6.3. MEA

6.3.1. MEA EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)

6.3.2. South Africa

6.3.2.1. South Africa EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)

6.3.2.2. Key Country Dynamics

6.3.2.3. Regulatory Framework

6.3.2.4. Reimbursement Scenario

6.3.2.5. Competitive Scenario

6.3.3. Saudi Arabia

6.3.3.1. Saudi Arabia EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)

6.3.3.2. Key Country Dynamics

6.3.3.3. Regulatory Framework

6.3.3.4. Reimbursement Scenario

6.3.3.5. Competitive Scenario

6.3.4. UAE

6.3.4.1. UAE EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)

6.3.4.2. Key Country Dynamics

6.3.4.3. Regulatory Framework

6.3.4.4. Reimbursement Scenario

6.3.4.5. Competitive Scenario

6.3.5. Kuwait

6.3.5.1. Kuwait EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)

6.3.5.2. Key Country Dynamics

6.3.5.3. Regulatory Framework

6.3.5.4. Reimbursement Scenario

6.3.5.5. Competitive Scenario

CHAPTER 7. COMPETITIVE LANDSCAPE

7.1. Company Categorization

7.2. Strategy Mapping

7.2.1. New Biomarker Launch

- 7.2.2. Partnerships
- 7.2.3. Acquisition
- 7.2.4. Collaboration
- 7.2.5. Funding
- 7.3. Key Company Market Share Analysis, 2024
- 7.4. Company Heat Map Analysis
- 7.5. Company Profiles
 - 7.5.1. F. Hoffmann-La Roche Ltd
 - 7.5.1.1. Company Overview
 - 7.5.1.2. Financial Performance
 - 7.5.1.3. Biomarker Benchmarking
 - 7.5.1.4. Strategic Initiatives
 - 7.5.2. QIAGEN
 - 7.5.2.2. Financial Performance
 - 7.5.2.3. Biomarker Benchmarking
 - 7.5.2.4. Strategic Initiatives
 - 7.5.3. Danaher Corporation
 - 7.5.3.1. Company Overview
 - 7.5.3.2. Financial Performance
 - 7.5.3.3. Biomarker Benchmarking
 - 7.5.3.4. Strategic Initiatives
 - 7.5.4. BD
 - 7.5.4.1. Company Overview
 - 7.5.4.2. Financial Performance
 - 7.5.4.3. Biomarker Benchmarking
 - 7.5.4.4. Strategic Initiatives
 - 7.5.5. bioMérieux
 - 7.5.5.1. Company Overview
 - 7.5.5.2. Financial Performance
 - 7.5.5.3. Biomarker Benchmarking
 - 7.5.5.4. Strategic Initiatives
 - 7.5.6. Abbott
 - 7.5.6.1. Company Overview
 - 7.5.6.2. Financial Performance
 - 7.5.6.3. Biomarker Benchmarking
 - 7.5.6.4. Strategic Initiatives
 - 7.5.7. Siemens Healthcare Private Limited
 - 7.5.7.1. Company Overview
 - 7.5.7.2. Financial Performance

- 7.5.7.3. Biomarker Benchmarking
- 7.5.7.4. Strategic Initiatives
- 7.5.8. Werfen
 - 7.5.8.1. Company Overview
 - 7.5.8.2. Financial Performance
 - 7.5.8.3. Biomarker Benchmarking
 - 7.5.8.4. Strategic Initiatives
- 7.5.9. Nova Biomedical
 - 7.5.9.1. Company Overview
 - 7.5.9.2. Financial Performance
 - 7.5.9.3. Biomarker Benchmarking
 - 7.5.9.4. Strategic Initiatives
- 7.5.10. Trividia Health, Inc.
 - 7.5.10.1. Company Overview
 - 7.5.10.2. Financial Performance
 - 7.5.10.3. Biomarker Benchmarking
 - 7.5.10.4. Strategic Initiatives

List Of Tables

LIST OF TABLES

Table 1 List of Secondary Sources

Table 2 List of Abbreviation

Table 3 EMEA Point-Of-Care Diagnostics Market, By Region, 2021 - 2033 (USD Million)

Table 4 EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)

Table 5 EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

Table 6 Europe EMEA Point-Of-Care Diagnostics Market, By Country, 2021 - 2033 (USD Million)

Table 7 Europe EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)

Table 8 Europe EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

Table 9 UK EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)

Table 10 UK EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

Table 11 Germany EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)

Table 12 Germany EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

Table 13 France EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)

Table 14 France EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

Table 15 Italy EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)

Table 16 Italy EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

Table 17 Spain EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)

Table 18 Spain EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

Table 19 Sweden EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033

(USD Million)

Table 20 Sweden EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033

(USD Million)

Table 21 Norway EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033

(USD Million)

Table 22 Norway EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033

(USD Million)

Table 23 Denmark EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033

(USD Million)

Table 24 Denmark EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033

(USD Million)

Table 25 MEA EMEA Point-Of-Care Diagnostics Market, By Country, 2021 - 2033 (USD Million)

Table 26 MEA EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)

Table 27 MEA EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

Table 28 South Africa EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)

Table 29 South Africa EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

Table 30 Saudi Arabia EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)

Table 31 Saudi Arabia EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

Table 32 UAE EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)

Table 33 UAE EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

Table 34 Kuwait EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD)

Table 35 Kuwait EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

List Of Figures

LIST OF FIGURES

- Fig. 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Market summary
- Fig. 4 Market segmentation & scope
- Fig. 5 Market size and growth prospects
- Fig. 6 EMEA Point-Of-Care Diagnostics market- Key market driver analysis
- Fig. 7 EMEA Point-Of-Care Diagnostics market - Key market restraint analysis
- Fig. 8 Penetration & growth prospect mapping
- Fig. 9 EMEA Point-Of-Care Diagnostics market - Porter's analysis
- Fig. 10 EMEA Point-Of-Care Diagnostics market - PESTEL analysis
- Fig. 11 EMEA Point-Of-Care Diagnostics market Product outlook key takeaways
- Fig. 12 EMEA Point-Of-Care Diagnostics market: Product movement analysis
- Fig. 13 Glucose Testing market estimates, 2021 - 2033 (USD Million)
- Fig. 14 Circulating Tumor Cells (CTCs) market estimates, 2021 - 2033 (USD Million)
- Fig. 15 Hb1Ac Testing market estimates, 2021 - 2033 (USD Million)
- Fig. 16 Coagulation Testing market estimates, 2021 - 2033 (USD Million)
- Fig. 17 Fertility/Pregnancy market estimates, 2021 - 2033 (USD Million)
- Fig. 18 Infectious Disease market estimates, 2021 - 2033 (USD Million)
- Fig. 19 HIV POC market estimates, 2021 - 2033 (USD Million)
- Fig. 20 Clostridium Difficile POC market estimates, 2021 - 2033 (USD Million)
- Fig. 21 HBV POC market estimates, 2021 - 2033 (USD Million)
- Fig. 22 Pneumonia or Streptococcus Associated Infections market estimates, 2021 - 2033 (USD Million)
- Fig. 23 Respiratory Syncytial Virus (RSV) POC market estimates, 2021 - 2033 (USD Million)
- Fig. 24 HPV POC market estimates, 2021 - 2033 (USD Million)
- Fig. 25 Influenza/Flu POC market estimates, 2021 - 2033 (USD Million)
- Fig. 26 HCV POC market estimates, 2021 - 2033 (USD Million)
- Fig. 27 MRSA POC market estimates, 2021 - 2033 (USD Million)
- Fig. 28 TB and Drug-resistant TB POC market estimates, 2021 - 2033 (USD Million)
- Fig. 29 HSV POC market estimates, 2021 - 2033 (USD Million)
- Fig. 30 COVID-19 market estimates, 2021 - 2033 (USD Million)
- Fig. 31 Urinalysis/Nephrology market estimates, 2021 - 2033 (USD Million)
- Fig. 32 Cardiac Markers market estimates, 2021 - 2033 (USD Million)

- Fig. 33 Thyroid Stimulating Hormone market estimates, 2021 - 2033 (USD Million)
- Fig. 34 Hematology market estimates, 2021 - 2033 (USD Million)
- Fig. 35 Primary Care Systems market estimates, 2021 - 2033 (USD Million)
- Fig. 36 Decentralized Clinical Chemistry market estimates, 2021 - 2033 (USD Million)
- Fig. 37 Feces market estimates, 2021 - 2033 (USD Million)
- Fig. 38 Lipid Testing market estimates, 2021 - 2033 (USD Million)
- Fig. 39 Cancer Marker market estimates, 2021 - 2033 (USD Million)
- Fig. 40 Blood Gas/Electrolytes market estimates, 2021 - 2033 (USD Million)
- Fig. 41 Ambulatory Chemistry market estimates, 2021 - 2033 (USD Million)
- Fig. 42 Drug of Abuse (DOA) Testing market estimates, 2021 - 2033 (USD Million)
- Fig. 43 Autoimmune Diseases market estimates, 2021 - 2033 (USD Million)
- Fig. 44 Urinalysis/Nephrology market estimates, 2021 - 2033 (USD Million)
- Fig. 45 EMEA Point-Of-Care Diagnostics market End Use outlook key takeaways
- Fig. 46 EMEA Point-Of-Care Diagnostics market: End Use movement analysis
- Fig. 47 Clinics market estimates, 2021 - 2033 (USD Million)
- Fig. 48 Pharmacy & Retail Clinics market estimates, 2021 - 2033 (USD Million)
- Fig. 49 Physician Office market estimates, 2021 - 2033 (USD Million)
- Fig. 50 Urgent Care Clinics market estimates, 2021 - 2033 (USD Million)
- Fig. 51 Hospitals market estimates, 2021 - 2033 (USD Million)
- Fig. 52 Home market estimates, 2021 - 2033 (USD Million)
- Fig. 53 Assisted Living Healthcare Facilities market estimates, 2021 - 2033 (USD Million)
- Fig. 54 Laboratory market estimates, 2021 - 2033 (USD Million)
- Fig. 55 Regional marketplace: Key takeaways
- Fig. 56 EMEA Point-Of-Care Diagnostics market: Regional movement analysis
- Fig. 57 Europe EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
- Fig. 58 UK EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
- Fig. 59 Germany EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
- Fig. 60 France EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
- Fig. 61 Spain EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
- Fig. 62 Italy EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
- Fig. 63 Denmark EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
- Fig. 64 Sweden EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
- Fig. 65 Norway EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
- Fig. 66 MEA EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
- Fig. 67 South Africa EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
- Fig. 68 Saudi Arabia EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)

Fig. 69 UAE EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)

Fig. 70 Kuwait EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)

Fig. 71 Strategy framework

I would like to order

Product name: EMEA Point-Of-Care Diagnostics Market Size, Share & Trends Analysis Report By Product (Glucose Testing, Cancer Marker, Coagulation Testing, Infectious Disease), By End-use (Clinics, Home), By Region (Europe, MEA), And Segment Forecasts, 2025 - 2033

Product link: <https://marketpublishers.com/r/E41936188EEEEEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E41936188EEEEEN.html>